Email this article Predictors of overall survival in patients with metastatic castration-resistant prostate cancer
- Authors: Markova A.S.1,2, Polikarpova S.B.1,2, Kamolov B.S.3,4, Gridneva Y.V.3,4, Kalinin S.A.5,6, Peters M.V.7,8, Matveev V.B.3,4
-
Affiliations:
- Department of Oncology, Faculty of Therapeutics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- 2 Bldg. 8, Trubetskaya St., Moscow 119992, Russia
- Urology Department, N.N. Blokhin Russian Cancer Research Center
- 23, Kashirskoe Shosse, Moscow 115478, Russia
- Department of Oncology and Radiotherapy, Faculty of Therapeutics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- 1, Ostrovityanov St., Moscow 117997, Russia
- Department of Oncology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
- 2/1, Barrikadnaya St., Moscow 125993, Russia
- Issue: Vol 11, No 2 (2015)
- Pages: 77-84
- Section: PROSTATE CANCER
- Published: 30.06.2015
- URL: https://oncourology.abvpress.ru/oncur/article/view/457
- DOI: https://doi.org/10.17650/1726-9776-2015-11-2-77-84
- ID: 457
Cite item
Abstract
Objective: to estimate overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC), who have received currently available drugs and to identify the predictors of OS.
Subjects and methods. The case histories of 112 patients with mCRPC treated at the N.N. Blokhin Russian Cancer Research Center in 2005 to 2014 were retrospectively analyzed. All the patients had received standard regimens based on docetaxel, cabazitaxel, abiraterone acetate in combination with prednisolone.
Results. Whatever the treatment option was, three-year OS rate was 32.0 ± 5.44 %; median survival was 24.3 months. The following poor prognostic factors for OS were pain syndrome; an ECOG performance status score of 2; the levels of prostate-specific antigen ≥ 288 ng/ml, lactate dehydrogenase ≥ 450 U/l, alkaline phosphatase ≥ 250 U/l, calcium < 2.28 mmol/l, and hemoglobin < 11.5 g/dl; as well as < 24 months’ duration of a response to hormonal therapy.
Conclusion. The use of standard drug treatment regimen for mCRPC may increase survival in this category of patients to achieve 3-years OV; and the identified factors of OV may aid in choosing treatment policy.
About the authors
A. S. Markova
Department of Oncology, Faculty of Therapeutics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; 2 Bldg. 8, Trubetskaya St., Moscow 119992, Russia
Author for correspondence.
Email: mark-an1@ya.ru
Russian Federation
S. B. Polikarpova
Department of Oncology, Faculty of Therapeutics, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; 2 Bldg. 8, Trubetskaya St., Moscow 119992, RussiaRussian Federation
B. Sh. Kamolov
Urology Department, N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115478, RussiaRussian Federation
Ya. V. Gridneva
Urology Department, N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115478, RussiaRussian Federation
S. A. Kalinin
Department of Oncology and Radiotherapy, Faculty of Therapeutics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1, Ostrovityanov St., Moscow 117997, RussiaRussian Federation
M. V. Peters
Department of Oncology, Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; 2/1, Barrikadnaya St., Moscow 125993, RussiaRussian Federation
V. B. Matveev
Urology Department, N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115478, RussiaRussian Federation
References
Supplementary files
